Company research
AN2 Therapeutics, Inc.
CIK 1880438Updated Sep 25, 2026
SecurityANTX · NASDAQ · equity
ANTX price & chart
Loading TradingView…
NASDAQ:ANTX on TradingView ↗About the company
AN2 Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on the discovery and development of novel small-molecule therapeutics derived from our boron chemistry platform. Our development pipeline spans hematologic diseases, infectious diseases, and oncology with three Phase 2 studies expected to be active in 2026, two preclinical candidates, as well as advanced research programs focused on targets in oncology, bone disorders, and infectious diseases. We are committed to delivering high-impact drugs to patients that address critical unmet needs and improve health outcomes.
In the news
Recent filings
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 61,950,000Source | 92,087,000Source | 138,744,000Source | 102,560,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 19,941,000Source | 21,351,000Source | 15,647,000Source | 27,219,000Source |
| Assets, CurrentUSD | 59,937,000Source | 86,262,000Source | 110,507,000Source | 98,621,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 1,936,000Source | 2,644,000Source | 3,212,000Source | 2,509,000Source |
| Other Assets, NoncurrentUSD | 0Source | 804,000Source | 1,043,000Source | 720,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 8,890,000Source | 10,238,000Source | 14,043,000Source | 7,188,000Source |
| Stockholders’ equity: | ||||
| Additional Paid in CapitalUSD | 293,953,000Source | 287,594,000Source | 278,881,000Source | 185,469,000Source |
| Retained Earnings (Accumulated Deficit)USD | -240,950,000Source | -205,776,000Source | -154,455,000Source | -89,723,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 57,000Source | 31,000Source | 275,000Source | -374,000Source |
| Stockholders' Equity Attributable to ParentUSD | 53,060,000Source | 81,849,000Source | 124,701,000Source | 95,372,000Source |
| Liabilities and EquityUSD | 61,950,000Source | 92,087,000Source | 138,744,000Source | 102,560,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 8,720,000Source | — | 14,043,000Source | 7,186,000Source |
| Operating Lease, Liability, CurrentUSD | — | — | — | 53,000Source |
| Accounts Payable, CurrentUSD | 3,021,000Source | 3,317,000Source | 2,676,000Source | 2,122,000Source |
| Other Liabilities, NoncurrentUSD | 170,000Source | — | — | — |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 2,052,000Source | 4,454,000Source | 6,681,000Source | 2,837,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | — | 99,300,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -35,174,000Source | -51,321,000Source | -64,732,000Source | -40,956,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | 6,246,000Source | 8,338,000Source | 8,412,000Source | 4,391,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts PayableUSD | -296,000Source | 641,000Source | 553,000Source | 2,497,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -29,834,000Source | -49,257,000Source | -53,288,000Source | -33,462,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 28,311,000Source | 54,589,000Source | -43,278,000Source | -21,771,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 113,000Source | 372,000Source | 84,994,000Source | 70,355,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -1,410,000Source | 5,704,000Source | -11,572,000Source | 15,122,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 19,941,000Source | 21,351,000Source | 15,647,000Source | 27,219,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Income Taxes Paid, NetUSD | 0Source | — | — | — |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 6,246,000Source | 8,338,000Source | 8,412,000Source | 4,391,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | — | 99,300,000Source |
| General and Administrative ExpenseUSD | 13,340,000Source | 14,066,000Source | 14,764,000Source | 12,751,000Source |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| Investment Income, InterestUSD | 2,934,000Source | 5,467,000Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | -35,174,000Source | -51,321,000Source | -64,732,000Source | -40,956,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -35,174,000Source | -51,321,000Source | -64,732,000Source | -42,776,000Source |
| Operating ExpensesUSD | 38,109,000Source | 56,788,000Source | 69,635,000Source | 42,262,000Source |
| Other Nonoperating Income (Expense)USD | 1,000Source | — | 4,903,000Source | -45,000Source |
| Payments to Acquire InvestmentsUSD | 46,189,000Source | 46,751,000Source | 132,178,000Source | 93,836,000Source |
| Proceeds from Issuance of Common StockUSD | 86,000Source | 147,000Source | 366,000Source | — |
| Proceeds from Stock Options ExercisedUSD | 27,000Source | 225,000Source | 99,000Source | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Operating Income (Loss)USD | -38,109,000Source | -56,788,000Source | -69,635,000Source | -42,262,000Source |
| Other Nonoperating Income (Expense)USD | 1,000Source | — | 4,903,000Source | -45,000Source |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -35,174,000Source | -51,321,000Source | -64,732,000Source | -40,956,000Source |
| Earnings Per Share, BasicUSD per share | -1.16Source | -1.72Source | -2.74Source | -2.79Source |
| Earnings Per Share, DilutedUSD per share | -1.16Source | -1.72Source | -2.74Source | -2.79Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 30,215,747Source | 29,828,227Source | 23,600,107Source | 15,340,134Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 30,215,747Source | 29,828,227Source | 23,600,107Source | 15,340,134Source |
| Additional Financial Items | ||||
| General and Administrative ExpenseUSD | 13,340,000Source | 14,066,000Source | 14,764,000Source | 12,751,000Source |
| Investment Income, InterestUSD | 2,934,000Source | 5,467,000Source | — | — |
| Investment Income, NetUSD | — | — | — | 1,351,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -35,174,000Source | -51,321,000Source | -64,732,000Source | -42,776,000Source |
| Operating ExpensesUSD | 38,109,000Source | 56,788,000Source | 69,635,000Source | 42,262,000Source |
| Preferred Stock Dividends and Other AdjustmentsUSD | — | — | — | 1,820,000Source |
| Research and Development ExpenseUSD | 24,769,000Source | 40,488,000Source | 54,871,000Source | 28,511,000Source |
Filing attachments
antx-ex99_1.htm · 8-K · 2026-08-11
EX-99.1 2 antx-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 AN2 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business and Scientific Highlights Expanding Phase 2 study start-up activities to support global trial of oral epetraborole in polycythemia vera Enrollment ongoing in Phase 2 investigator-initiated trial of epetraborole for M. abscessus lung disease Positive non-human primate efficacy and favorable Phase 1 clinical pharmacokinetics and safety profile support p…
Read attachment ↗d247428dex991.htm · 8-K · 2026-06-04
EX-99.1 2 d247428dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 AN2 Therapeutics Reports Positive Enabling Data Supporting Advancement of Oral AN2-502998 to Phase 2 Study for Chronic Chagas Disease Parasite elimination achieved with 28-day treatment in 100% of nonhuman primates (NHPs) naturally infected with Trypanosoma cruzi (T. cruzi) at target exposures planned in humans Phase 1 First-In-Human (FIH) study showed favorable safety and tolerability profile; no dose-limiting toxicities Signif…
Read attachment ↗antx-ex99_1.htm · 8-K · 2026-05-11
EX-99.1 2 antx-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 AN2 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business and Scientific Highlights Oral epetraborole program in polycythemia vera advancing toward Phase 2 Phase 2 investigator-initiated trial with epetraborole for M. abscessus lung disease underway Data expected in 2Q/2026 from two studies of oral AN2-502998, under development for chronic Chagas disease: a Phase 1 first-in-human clinical trial and a non-huma…
Read attachment ↗antx-ex99_1.htm · 8-K · 2026-03-17
EX-99.1 2 antx-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 AN2 Therapeutics Reports Fourth Quarter and Full Year End 2025 Financial Results and Recent Business and Scientific Highlights Phase 2 study of oral epetraborole in polycythemia vera (PV) expected to begin 3Q26 with potential for data readouts as early as 4Q26 and throughout 2027 Advancing Phase 2 investigator-initiated trial of epetraborole in M.abscessus complex lung disease; Enrollment expected to begin in 1Q26 with topline result…
Read attachment ↗d14366dex41.htm · 8-K · 2026-03-10
EX-4.1 2 d14366dex41.htm EX-4.1 EX-4.1 Exhibit 4.1 THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON THE EXERCISE OF THIS WARRANT (THE “SECURITIES”) HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES OR IN ANY OTHER JURISDICTION. THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE OFFERED, SOLD, TRANSFERRED OR ASSIGNED UNLESS (I) SUCH SECURITIES HAVE BEEN REGISTERED FOR S…
Read attachment ↗d14366dex991.htm · 8-K · 2026-03-10
EX-99.1 5 d14366dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 AN2 Therapeutics Announces $40 Million Private Placement Financing MENLO PARK, Calif. - (BUSINESS WIRE) - AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that it has entered into a securities purchase agreement for a private placement that is expected to result in gross proceeds of approximately $4…
Read attachment ↗